Morgan Stanley Comments on Pfizer Meeting

In a research report published earlier today, Morgan Stanley commented on the recent Pfizer

Emerging Markets & Established Products meeting. According to Morgan Stanley, “On Friday March 30th, we met with David Simmons, President of Emerging Markets (

) and Established Products (

), and Susan Silverman, Head of LatAm. We found both to be quite impressive and direct. EM and EP are each approximately $10 billion operations (each 15% of total Pfizer revenue). Four takeaways were: 1) we expect Pfizer to retain EP, 2) generics M&A likely to be niche, 3) U.S. Lipitor strategy is working, and 4) EM should accelerate.” Morgan Stanley maintains its Overweight rating on Pfizer, which closed Friday at $22.66.